



# Workshop on development of antibacterial medicinal products for paediatric patients

---

21–22 June 2018  
European Medicines Agency  
London, United Kingdom

# Objectives

---

To explore - together with relevant stakeholders - development plans that would allow for the timely development of antibacterials for children and discuss EMA, FDA and PMDA data requirements for their approval;

To discuss relevant aspects to antibacterial development in children, including challenges with conducting trials in the paediatric population (including neonates), and extrapolation of safety and efficacy data to optimise the involvement of children in clinical studies;

To gather further feedback on the draft EMA/CHMP [Addendum to the guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections to address paediatric-specific clinical data requirements](#) (EMA/CHMP/187859/2017) (currently on public consultation until end of October 2018).

# Programme details

Meeting room 3-A

Thursday, 21 June 2018

Order of presentations subject to change

**08:30**

**Registration**

---

**09:00**

**Welcome and introduction**

---

**Marco Cavaleri**, EMA; **Edward Cox**, FDA; **Junko Sato**, PMDA

15'

**09:15**

**Session 1: General considerations on regulatory requirements**

---

Chair: **Edward Cox**, FDA; **Marco Cavaleri**, EMA

**EMA view: the paediatric Addendum to the antibacterial agents Guideline**

**Maria Jesús Fernández Cortizo**, IDWP

30'

**FDA view: ongoing activities and requirements for developing antibacterial agents for children in the US**

**John Farley**, FDA

30'

**PMDA perspective: ongoing activities and requirements for developing antibacterial agents for children in Japan**

**Junko Sato**, PMDA

30'

**10:45**

**Coffee break**

---

**11:00**

**Session 2: Challenges with paediatric trials**

---

Chair: **Sumathi Nambiar**, FDA, **Irmgard Eichler**, EMA

**Investigator's perspective**

**John Bradley**, University of California, US

30'

**Tuuli Metsvaht**, University of Tartu, EE

30'

**Industry's view**

**Dr. Gary Noel**, J&J

15'

**Dr. Sue Cammarata**, Melinta, USA

15'

**Discussion**

30'

**13:00**

**Lunch break**

---

---

**14:00**      **Session 3: Efficacy Assessment**

---

Chair: **Irja Lutsar**, PDCO; **Danny Benjamin**, Duke Clinical Research Institute, Durham, USA

***Paediatric pharmacokinetics, PK/PD and extrapolation***

**Joseph Standing**, University College London, UK 30'

***Clinician's view***

**Michael Cohen-Wolkowicz**, Duke University, Durham, USA 30'

***Industry's view***

**Dr. Margaret Tawadrous**, Pfizer 30'

***Discussion***

30'

---

**16:00**      **Coffee break**

---

---

**16:15**      **Session 4: Studying neonates**

---

Chair: **Ralph Bax**, EMA; **John Bradley**, University of California, USA;

***Overview***

**Maria Jesús Fernández Cortizo**, IDWP; **Sumathi Nambiar**, FDA 30'

***Clinical aspects***

**Danny Benjamin**, Duke Clinical Research Institute, Durham, USA 20'

***PK aspects***

**Karel Allegaert**, Catholic University Leuven, BE 20'

***Developers'/Industry's view***

**Dr. Balasegaram**, GARDP 20'  
**Dr. Matthew Johnson**, MSD 10'

***Discussion***

30'

---

**18:25**      **End of day 1**

---

**09:30**      **Welcome and introduction**

---

**09:40**      **Session 5: Safety Assessment**

---

Chair: **Dirk Mentzer**, PDCO, **John Farley**, FDA

***Clinician's view***

**Mike Sharland**, St George's University of London, UK

15'

**John Bradley** University of California, USA

15'

***Industry's view***

**Dr. Hasan Jafri**, MedImmune

30'

***Discussion***

60'

**11:40**      **Wrap-up**

---

Chair: **Marco Cavaleri**, EMA; **Edward Cox**, FDA; **Junko Sato**, PMDA

20'

**12:00**      **End of workshop**

---

**Acronyms**

*By alphabetic order*

GARDP - *Global Antibiotic Research and Development Partnership*

EMA - *European Medicines Agency*

FDA - *Food and Drug Administration*

IDWP - *Infectious Disease Working Party*

PDCO - *Paediatric Committee*

PK/PD - *Pharmacokinetic-pharmacodynamic*

PMDA - *Pharmaceuticals and Medical Devices Agency*

# Practical information

## Venue

The European Medicines Agency can be reached:

- **By Underground**

The nearest stop for Churchill Place is Canary Wharf station on the Jubilee Line. From East exit N.B. This is the closest exit to 30 Churchill Place): exit the station and turn left into Upper Bank Street, turn right at Canada Square and continue straight into Churchill Place.

- **By Docklands Light Railway (DLR)**


The Agency is a short walk from Canary Wharf station on the DLR. Services run from Bank, Tower Gateway, Lewisham, Stratford, King George V and Beckton. Exit into The South Colonnade, turn left towards Canada Square continuing straight into Churchill Place.

- **By car**

There are no parking facilities at 30 Churchill Place and it is recommended that you take public transport. However, four nearby public car parks are operated by Canary Wharf. Rates and further information can be found on the Canary Wharf website:

<http://www.canarywharf.com/aboutus/The-Estate/Travel-/Roads--Parking/>

## Map



## Arrival at the Agency

---

On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to access our industry lounge, which you are welcome to utilise during your visit. The industry lounge is located through the sliding doors to the right of the reception desk past the security turnstiles. Your EMA contact point will meet you here.

## Physical disability

---

Let us know if you would like any specific help or information that would make your stay more comfortable. We will be very happy to help.

## Registration

---

We strongly advise you to arrive up to 30 minutes before the start of the workshop, to allow you time for registration and settling down.

## Meeting room

---

Upon arrival each day, please find your allocated seat in the meeting room. Speakers will be able to navigate through their presentation slides from their seats with a pointer, mouse or keyboard.

## Presentations

---

We will not circulate printouts of speakers' presentations. However, you will be able to download them from the Agency's website approximately two weeks after the end of the workshop:  
<http://www.ema.europa.eu/ema/>

## Wi-Fi access & laptop computers

---

Wi-Fi is available throughout the EMA. Login details can be found on the back of your EMA access pass.

## Media disclaimer

---

The Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency as enshrined in the Treaty on European Union. The Agency herewith informs attendees that this particular meeting will be recorded and broadcast. For more information about processing of personal data by EMA, please visit the website:

[http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general\\_content\\_000516.jsp&mid](http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general_content_000516.jsp&mid)  
or contact  
[dataprotection@ema.europa.eu](mailto:dataprotection@ema.europa.eu)

By attending this meeting you consent to any recording or broadcast.

## Conference venue and secretariat

---

European Medicines Agency  
30 Churchill Place, Canary Wharf  
London E14 5EU, United Kingdom  
**Telephone** +44 (0)20 3660 7259 | **Facsimile** +44 (0)20 3660 5550  
**E-mail** [jolanta.palepsaitiene@ema.europa.eu](mailto:jolanta.palepsaitiene@ema.europa.eu) | **Website** [www.ema.europa.eu](http://www.ema.europa.eu)

For any questions prior to the workshop in relation to the content and participation, please write to [Paediatric.antibacterial.agents.workshop@ema.europa.eu](mailto:Paediatric.antibacterial.agents.workshop@ema.europa.eu)